Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest the PD-L1 inhibitor measures up to Pfizer’s PD-1 ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...
In the closing months of 2025, President Donald Trump’s effort to reshape how Americans pay for prescription drugs has taken clearer form. What started as a campaign threat to slap tariffs on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback